GLPwatch
Papers (12034)
Page 152 of 201, ranked by citation count.
- Effects of Tirzepatide on Low-Density Lipoprotein Cholesterol Levels in Adults: A Systematic Review.
- Unlocking the potential of microfluidic assisted formulation of exenatide-loaded solid lipid nanoparticles.
- [Effect of liraglutide on glucagon secretion in obese type 2 diabetic patients].
- Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- The GLP-1 analog, exendin-4, improves bone material properties and strength through a central relay in ovariectomized mice.
- Ozempic keeps wowing: trial data show benefits for kidney disease.
- Changes in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide.
- Shifts in body mass index category with tirzepatide and associated changes in cardiometabolic risk factors in people with obesity: a post hoc analysis from the SURMOUNT-1 and SURMOUNT-4 trials.
- Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice.
- The role of mast cells in cellular modifications evoked by Exendin-4 in treated wounds: a preclinical study.
- Gastrointestinal adverse events of semaglutide in patients with overweight or obesity.
- Impact of Fasting on Physical Activity Motivation and Weight Reduction in Patients Administered Glucagon-Like Peptide-1 Agonists: A Qualitative Study.
- In brief: GI effects of GLP-1 receptor agonists.
- Incretins and amylin in pediatric diabetes: new tools for management of diabetes in youth.
- Evaluation of A Novel GLP-1R Ligand for PET Imaging of Prostate Cancer.
- Treatment persistence, adherence and healthcare resource utilisation for iGlarLixi versus basal-bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: SoliEthnicity study.
- Semaglutide in NASH-related cirrhosis: still a long way to go? - Authors' reply.
- Cost consequence analysis of adding semaglutide to treatment regimen for patients with Type II diabetes in Saudi Arabia.
- Impact of chemical structure, lipidation and formulation on luminal stability and intestinal absorption of GLP-1 analogues.
- More on Semaglutide in Early Type 1 Diabetes.
- [Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
- Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
- [Impact on weight loss and body composition of a food education intervention associated with Liraglutide treatment to address obesity].
- Does Semaglutide Reduce Kidney Disease Events on Top of SGLT2 Inhibitors in Patients with CKD and T2D?
- Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.
- A call to update anesthetic protocols: the hidden risks of semaglutide.
- One-year Efficacy and Safety of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Study of Asian Patients.
- Comparing diabetes drugs--helping clinical decisions?
- Obesity treatment as a bridge to solid organ transplantation: A comparison of bariatric surgery to medical therapy.
- AI-Driven De Novo Design of Ultra Long-Acting GLP-1 Receptor Agonists.
- Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis.
- Semaglutide and the pathogenesis of progressive neurodegenerative disease: the central role of mitochondria.
- Semaglutide: FDA publishes warning amid reports of patients overdosing.
- Design of potent and proteolytically stable double biaryl-stapled GLP-1R/GIPR peptide dual agonists.
- [GLP-1-based medications: Mechanisms involved in obesity treatment].
- Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide.
- The Welander TIA1 mutation dedifferentiates insulin-producing cells: Reversal by a GLP-1 receptor agonist.
- Erratum. Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2020;43:1813-1821.
- Diabetes: Cardiovascular benefits of semaglutide.
- Comparing Efficacy and Safety of Different Doses of Tirzepatide for the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
- Study: Semaglutide Lowered Chronic Kidney Disease-Related Risks.
- Medication Adherence to Semaglutide versus Empagliflozin in Adults with Type 2 Diabetes: A Retrospective Observational Study in Saudi Arabia.
- Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
- Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis.
- Effects of Liraglutide on Leptin Promoter Methylation in Ovarian Granulosa Cells of Patients with Polycystic Ovary Syndrome and Obesity.
- GLP-1 and GIP agonists in diabetes and obesity and the rise of dyspepsia.
- Engineering Marker-Free Lettuce Chloroplast Genome to Express Functional Glucagon-Like Peptide-1 Receptor Agonists Exenatide and Lixisenatide.
- Utilization of antiobesity medications within the Military Health System.
- Cardiovascular Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes Mellitus With Atherosclerotic Cardiovascular Disease: A Systematic Review of Randomized Controlled Trials.
- The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review.
- Effect of Tirzepatide in an Adolescent With Early-Onset Obesity, Hyperphagia, and Type 2 Diabetes.
- In poorly controlled type 2 diabetes, oral semaglutide was noninferior to liraglutide for reducing HbA1c.
- Hypersensitivity to liraglutide: A case report.
- Liraglutide orchestrates ferroptosis defense against murine cisplatin acute kidney injury: NRF2 activation via both KEAP1-dependent and -independent mechanisms is essential for SLC7A11/GPX4 renoprotection.
- Cost-benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand.
- One small STEP, one giant leap: Semaglutide in the obese phenotype of heart failure with preserved ejection fraction.
- Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide.
- A case report of severe adverse reaction of exenatide: Anaphylactic shock.
- Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
- Both subcutaneous semaglutide and calorie restriction improves pancreatic cell hyperplasia and gut microbiota in high-fat diet-induced obese mice.